Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

NCT02598297 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

49

Enrollment

INDUSTRY

Sponsor class

Stopped Unresolvable inability to recruit the patients.

Conditions

Myelofibrosis With High Molecular Risk Mutations

Interventions

DRUG: Ruxolitinib
DRUG: Ruxolitinib Placebo

Sponsor

Novartis Pharmaceuticals